About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Obesity and Pediatric Multiple Sclerosis | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNCT04593082

Obesity and Pediatric Multiple Sclerosis

Obesity is one possible contributor to severity of multiple sclerosis and progression of the disease. We already know that obesity is a risk determinant for acquiring MS, yet the impact of obesity on ...

Lead sponsor: University of Virginia•2 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

J Nicholas Brenton, MD

CONTACT

434-982-3936 [email protected]

Margaret Keller

CONTACT

434-297-4102 [email protected]

Sponsors

Lead Sponsor

University of Virginia

Collaborators

Children's Hospital of Philadelphia

Age

10 - 20 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Ability to provide informed consent (or assent for minors)
•Relapsing-remitting MS diagnosis per 2017 McDonald criteria
•Ages ≥ 10 years to ≤ 20 years
•Diagnosis of MS or first clinical symptom of MS (whichever comes first) within ≤ 36 months from the time of enrollment.
•Ability to provide informed consent (or assent for minors)
•Age-, sex-, \& BMI-matched to pediatric MS subjects (1:1 allocation)
•Healthy children and young adults from the local communities

Exclusion Criteria

•Progressive form of MS
•Patients with an active, chronic disease of the immune system other than MS
•Conditions affecting the central nervous system (CNS) white matter (e.g. leukodystrophy) or for whom another condition may better explain imaging abnormalities (e.g. lupus)
•Myelin oligodendrocyte glycoprotein (MOG) antibodies on serologic testing
•Corticosteroid exposure within 30 days of study enrollment
•History of past imaging or neurologic event raising concern for any inflammatory CNS process
•Medical history or previous/current diagnosis consistent with an autoimmune disorder pertaining to any system of the body (e.g. diabetes mellitus type 1, Crohn's disease, lupus)

Related studies

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

NCT06433752 · Relapsing Multiple Sclerosis, Multiple Sclerosis

RECRUITINGPhase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281 · Relapsing Multiple Sclerosis

Nomad P-KAFO Study

NCT05644522 · Cerebrovascular Accident, Post-polio Syndrome, and more

RECRUITINGPhase 2

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

NCT07497399 · Multiple Sclerosis

RECRUITINGPhase 3

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

NCT06847724 · Relapsing Multiple Sclerosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 9, 2024Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment116

Start dateJun 2021

Last updatedDec 9, 2024

Condition

Multiple Sclerosis

Locations shown

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania

University of Virginia

Charlottesville, Virginia

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 9, 2024Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions